My name’s Ethan White and I’m currently trying to finish my PhD in Evolutionary Psychology. I’m interested in the evolution of creativity and language and how it relates to sexual and relationship behavior.

If anyone would be interested I have a survey I’d like you to take which would really help me out. It shouldn't take more than an hour and some people finish it in around 30 minutes.

Now you might say, "I don’t know you, you pervert. I'm not telling you any of that.

To which I would respond, "Good call.

PHILADELPHIA and LONDON, June 17 /PRNewswire/ --

- BIOMARKERcenter is First Comprehensive and Quality Assured Biomarker Solution Available to the Pharmaceutical Industry

Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced today the launch of BIOMARKERcenter, a unique comprehensive resource for biomarker intelligence. This new solution will be the first to provide the pharmaceutical industry with a framework for assessing the potential of a biomarker and to be alerted of any changes in their status.

TORONTO, Ontario, June 17 /PRNewswire/ --

- Latest Evidence for Businesses to Justify Investing in Pandemic Preparedness Plans

TORONTO, Ontario, June 17 /PRNewswire/ --

The Schulich School of Business today released the first study to assess the impact of an influenza pandemic on individual companies. Presented today at the World Conference on Disaster Management, the study - Making a case for investing in pandemic preparedness - focuses on how companies can justify investing in pandemic planning using standard business performance metrics. The study highlights that an investment now far outweighs the potential impact that a pandemic could have on individual businesses.

LONDON, June 17 /PRNewswire/ --

- Building Virtual Careers Provides Fully Interactive Experience That Eliminates Hassles of Traditional Career Fairs

A 'virtual' careers fair being held June 18-19 can lead to real jobs for those working in the construction industry.

Building Virtual Careers is a fully interactive online experience, from Building, the market-leading construction publication.

The event will include exhibitor booths and allow registrants to chat with leading companies in the construction industry, as well as other attendees, in real time.

BASINGSTOKE, UK and PHILADELPHIA, US, June 17 /PRNewswire/ --

Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda(TM) (mesalamine). The primary endpoints of this study were to assess the safety and tolerability of Lialda in mild-to-moderate UC patients over 12 months. Data were published in the July issue of Gut, the official journal of the British Society of Gastroenterology , a leading international journal in gastroenterology.

MILWAUKEE, Wisconsin, June 17 /PRNewswire/ --

- First World Allergy Report Calls for Urgent Worldwide Collaboration to Tackle Global Increase in Allergies and Allergic Diseases

ATLANTA and LONDON, June 17 /PRNewswire/ --

IntercontinentalExchange (NYSE: ICE), a leading operator of global derivatives exchanges and over-the-counter (OTC) markets, today announced that the Commodity Futures Trading Commission (CFTC) staff has proposed conditions amending the "no-action relief letter" granted to its U.K. subsidiary, ICE Futures Europe(TM).

SAN DIEGO, June 17 /PRNewswire/ --

- Strong Government Support Continues to Draw Top Research Institutes, Talent, and Corporate Labs That Are Looking to Place Strategic Bets for the Future

Singapore's investment of more than US$2.1 billion in the biomedical sciences sector has seeded one of the fastest growing bioclusters in the world. R&D spending in the biomedical sciences grew by more than 24% to reach US$760 million in 2006 (from 2005), while the number of research scientists and engineers working in the sector has similarly grown by more than 12% to exceed 2,000 people.

How is it that a statement by the Vatican has delayed my annual report to the National Institutes of Health? Not being Catholic, I generally don't pay much attention to Papal announcements, but maybe I need to start listening. Apparently back in March, the Vatican suggested that "genetic manipulations which alter DNA" are mortal sins.

Since just about everything I do in the lab involves genetic manipulations which alter DNA (in fact the only organisms in our lab which aren't genetically engineered are the people who work there), I can add one more item to my long list of reasons for why I'm headed to eternal condemnation.

But before I get to Hell, I need to submit my annual NIH Fellowship update. I have a fellowship from the National Institutes of Health, which pays my not-so-large salary. In return for the money, I tell the NIH what I've been doing every year. That's fair enough - the NIH should expect something for their money.

Everything that I have done this year, however, has involved some sort of genetic engineering - which apparently upsets the Pope. This is unfortunate, because if we eliminated all genetic engineering, essentially all biomedical research would grind to a halt. Genetic engineering, in some restricted applications, has its risks, but the vast majority of genetic engineering that goes on every day in thousands of labs all over the world is essential to our efforts to understand both basic biology and the impact of genes on our health.

STOCKHOLM, June 17 /PRNewswire/ -- Karolinska Development announced that the talk will focus on the commercialization mechanism behind the Karolinska Institutet Innovations System set up by Karolinska Institutet. Bogentoft, is CEO of Karolinska Development (KD), one of the largest life science investment companies in Europe. Using a unique highly cost effective model to commercialize innovative life science from Northern Europe KD capitalizes on the value appreciation generated by bringing very early projects to proof of concept.

This talk will cover the key points that have enabled KD to build a portfolio in less than 5 years that, has three companies with products on the market; four with compounds at phase II and five with compounds at phase I.